Search / Trial NCT06616532

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Launched by BIOTHEUS INC. · Sep 25, 2024

Trial Information

Current as of October 04, 2024

Not yet recruiting

Keywords

Second Line

Description

This multicenter, randomized, open-label phase III study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel versus Investigator's Choice (Topotecan or Paclitaxel) as second-line treatment for subjects with SCLC.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Voluntary participation in this clinical study; full understanding of the study and voluntary signing the informed consent form; willing to follow and abling to complete all trial procedures;
  • 2. Age ≥18 years but ≤75 years;
  • 3. Histologically or cytologically confirmed SCLC;
  • 4. Advanced SCLC that has progressed or replased after first-line platinum-containing chemotherapy (extensive-stage patients must have received immune checkpoint inhibitors);
  • 5. Having adequate organ functions;
  • 6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;
  • 7. Life expectancy of 12 weeks or more;
  • 8. Having at least one measurable tumor lesion according to RECIST v1.1;
  • Exclusion Criteria:
  • 1. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;
  • 2. Previous treatment with Paclitaxel or Topotecan or anti-vascular endothelial growth factor (VEGF) target drugs;
  • 3. Current presence of severe superior vena cava syndrome and spinal cord compression;
  • 4. Adverse events resulting from prior anti-tumor therapies should be assessed and graded according to the CTCAE 5.0 criteria, subjects whose AEs have not returned to Grade 1 or below;
  • 5. Evidence of significant clotting disorder or other significant bleeding risk;
  • 6. History of severe, uncontrollable, or active cardiovascular diseases within 6 months;
  • 7. Current presence of uncontrollable pleural, pericardial, and peritoneal effusions;
  • 8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome;
  • 9. History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation;
  • 10. History of alcohol abuse, psychotropic substance abuse or drug abuse;
  • 11. Pregnant or lactating women;
  • 12. Other conditions considered unsuitable for this study by the investigator.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Changchun, , China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0